Analysts Set Expectations for Medicus Pharma Q1 Earnings

Medicus Pharma Ltd. (NASDAQ:MDCX) – Stock analysts at Brookline Capital Management issued their Q1 2025 earnings estimates for Medicus Pharma in a research note issued on Tuesday, April 8th. Brookline Capital Management analyst K. Raja forecasts that the company will earn ($0.23) per share for the quarter. Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for Medicus Pharma’s current full-year earnings is ($1.14) per share. Brookline Capital Management also issued estimates for Medicus Pharma’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.23) EPS and FY2029 earnings at $1.68 EPS.

Separately, Maxim Group initiated coverage on Medicus Pharma in a research report on Tuesday, December 17th. They set a “buy” rating and a $10.00 target price for the company.

Medicus Pharma Price Performance

Shares of MDCX stock opened at $3.58 on Thursday. Medicus Pharma has a 1 year low of $1.80 and a 1 year high of $6.00. The company has a 50 day moving average of $3.44.

Medicus Pharma (NASDAQ:MDCX) last announced its earnings results on Friday, March 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14.

Hedge Funds Weigh In On Medicus Pharma

An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new stake in Medicus Pharma Ltd. (NASDAQ:MDCX) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma comprises about 1.3% of Interchange Capital Partners LLC’s portfolio, making the stock its 15th biggest holding. Interchange Capital Partners LLC owned 13.43% of Medicus Pharma at the end of the most recent reporting period.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.